AzTrials
AzTrials

OCDNCT03926546

Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)

A study testing ERP for Individuals in people with OCD, run by Baylor College of Medicine at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The primary objective is to examine the efficacy of implementing evidence based Exposure and Response Prevention (ERP) within group therapy versus individual therapy by monitoring reduction of Obsessive-Compulsive Disorder (OCD) symptomology. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
OCD
What is being tested?
ERP for Individuals
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
May 2020to Feb 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants must be adults 18 years or older.
  • Participants must have the capacity and ability to give informed consent.
  • Participants have been given an assessment and received a diagnosis of OCD.
  • Participants must speak English.
  • Participants must be able to physically attend treatment.

Who cannot join

  • Prisoners or any other high-risk population group.
  • experiencing active psychosis
  • experiencing active substance abuse disorder
  • experiencing active suicidality

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baylor College of Medicine Jamail Building

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Individual Versus Group Exposure and Response Prevention Therapy for the Treatment of Obsessive-Compulsive Disorder

The primary objective is to examine the efficacy of implementing evidence based Exposure and Response Prevention (ERP) within group therapy versus individual therapy by monitoring reduction of Obsessive-Compulsive Disorder (OCD) symptomology.

Read the detailed description

The purpose of the following study is to observe the effectiveness of group Exposure and Response Prevention verses individual Exposure and Response Prevention on patients with OCD for the use of future publications.

A total of 70 individuals will be recruited through different methods. The primary recruitment sources will be through BCM Psychiatric Clinic patient flow. Although it is anticipated that most of the study recruitment will occur through normal BCM Psychiatric Clinic patient flow, study advertisements will also be circulated through several relevant sources (e.g. BCM OCD Program website, Peace of Mind Foundation website and listserv, social media pages and OCD organizations and groups). The investigators will also contact clinicians and professionals working with OCD patients (e.g., private clinics, community organizations) in the community to distribute advertisement flyers to potential participants.

Enrollment will occur in person at Baylor College of Medicine after obtaining informed consent.

Pertinent clinical information will be collected from paper or electronic medical records. Demographics (race, ethnicity, gender, education, employment status), and health history (concomitant medical history) will be collected and entered in the database. Data entered in the database will be coded. Patient identifying information such as name, address, telephone, date of birth, and medical record number will be extracted from the medical record. A study ID will be assigned to each subject. The code linking the consented subjects' clinical information to their study ID will be stored in a password protected database. The code linking key containing patient identifying information will be kept separately from the database. Any relevant paperwork, including videos, will be stored in a locked file cabinet in the PIs office.

Prospective data collection will continue for those subjects that consent to participate in the study.

Investigators wishing to utilize the information collected in this database must show proof of an IRB approved protocol that will be reviewed by the PI of this database registry before information can be released. Depending on the purpose of the research, data will be shared without identifiers if possible. If requested, data can be sent coded to the investigator. Only those subjects that fit inclusion criteria for the proposed research and specify that they consent to be contacted about other research will be shared with the other requesting investigators. Other investigators will not have access to the document that links coded data to identifiers.

Participants will be randomly assigned (1:1) to receive either individual therapy (i.e., 12 individual ERP sessions, each 45-60 minutes, offered twice weekly for a total of six weeks) or group therapy (a total of 6 group ERP sessions, each 120 minutes, offered weekly for 6 weeks). Sessions will be led by an ERP trained mental health professional or trainee under the supervision of a licensed mental health professional. Both the individual and group participants will receive a total of 12 hours of ERP over the span of six weeks. However, those assigned to group therapy will meet for 2 hours weekly versus those assigned to individual therapy will meet for 1 hour twice weekly. Each session will consist of completed measures and therapy involving ERP for the entirety of the six weeks. Participants assigned to the group therapy protocol will be placed in groups, each consisting of 5-8 individuals, with two therapists per group.

In the groups, Session 1 will focus on psychoeducation about ERP and OCD. Sessions 2-5 will involve ERP tasks. Session 6 will focus on relapse prevention strategies. In individual treatment, Session 1 will focus on psychoeducation, sessions 2-10 on ERP, 11-12 on relapse prevention.

All patients will voluntarily participate in assessments with the researcher while also completing self-reported measures. All clinician-rated assessments will be conducted with an independent evaluator (IE). The demographic data will be collected at the beginning of treatment, Baseline. The Y-BOCS and self-report Y-BOCS will be administered at Baseline and Post-treatment. The Clinical Global Impression-Severity, OCD Identity Questionnaire, Sheehan Disability Scale, Depression Anxiety Stress Scale-21 (DASS-21) Item Version and the Quality of Life (Q-LESQ-SF)-21 will be administered at Baseline, Mid treatment and Post-treatment to track patient symptomology. The weekly feedback measure will be administered every session to participants to collect data on their thoughts of how treatment is going. The following list of measures will be administered.

Researcher Administered:

  1. Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
  2. Self-report Yale-Brown Obsessive-Compulsive Scale
  3. NIMH Global Obsessive-Compulsive Scale (NIMH-GOCS)
  4. Clinical Global Impression-Severity/Improvement *

Self-Administered:

  1. Demographic Form - Baseline
  2. Sheehan Disability Scale- Baseline, Mid treatment and Post-treatment
  3. OCD Identity Questionnaire- Baseline, Mid treatment and Post-treatment
  4. Depression Anxiety Stress Scale - 21 Item Version (DASS-21) - Baseline, Mid treatment and Post-treatment
  5. Quality of Life-21 (Q-LESQ-SF) - Baseline, Mid treatment and Post-treatment
  6. Weekly Feedback Measure - Every session

The investigators will enroll all eligible subjects. A total of 70 individuals will participate. This number is anticipated based on group and individual dyad enrollment.

Descriptive analyses of participant data will be ongoing for one year, the entire duration of the study. For this study, descriptive statistics and symptomology improvements/ regressions analyses will be used to analyze study variables. Measures will be analyzed for use of future publications surrounding ERP treatment for OCD in groups and individual settings.

Conditions
OCD
Being tested
ERP for Individuals

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ERP for IndividualsBehavioural

    Also called ERP for Groups

    Comparing Group vs. Individual ERP for OCD

Study groups in NCT03926546
Study groupRoleWhat they receive
Individual ERPExperimentalIndividual Exposure and Response Prevention for OCD
Receives: Behavioral: ERP for Individuals
Group ERPExperimentalGroup Exposure and Response Prevention for OCD
Receives: Behavioral: ERP for Individuals

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Yale-Brown Obsessive-Compulsive Scale

    Participant OCD severity is measured with Yale-Brown Obsessive-Compulsive Scale over the course of their time in the study. Severity is measured at baseline (week 1), mid (week 3), and post (week 6) participation in ERP over the course of 6 weeks. Severity on the scale is measured based on a score range of 0-40. Participants with scores of 0-13 are considered to have mild symptoms. Scores of 14-25 are considered moderate. 26-34 are considered to be moderate-severe. 35-40 are considered to be very severe.

    Measured: Post-treatment, 6 weeks after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2019
  2. Study startMay 2020 (estimated)
  3. Primary completionDec 2020 (estimated)
  4. Study completionFeb 2021 (estimated)

Why it stopped: The former principal investigator left the institution.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03926546
Sponsor's protocol ID
H-44611
Status last verified
May 2020
First submitted
9 Jan 2019
Last updated
27 May 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ERP for Individuals in people with OCD, run by Baylor College of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 27 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Yale-Brown Obsessive-Compulsive Scale (time frame: Post-treatment, 6 weeks after baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in